Manganese in Women With Encephalopathy
Report manganese serum levels and mortality in encephalopathic patients.
Patients and participants:
Consecutive patients aged > 18 years, with hepatic encephalopathy and informed consent signed by their families.
Patients' clinical characteristics as well as biochemical tests of renal function, hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze manganese levels with a graphite furnace atomic absorption spectrometer.
There is a difference in the manganese levels between male and female patients.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy|
- Clinical Evolution [ Time Frame: six months ] [ Designated as safety issue: No ]Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room
- Manganese Levels [ Time Frame: Up to six months we followed the recruited patients to determine who were still alive ] [ Designated as safety issue: No ]From encephalopathic patients, we took individual blood samples, analyzed in the biochemistry laboratory at the National Institute of Neurology and Neurosurgery, Mexico, City, with a graphite furnace atomic absorption spectrometer, according to the technique reported by Pleban.
|Study Start Date:||January 2003|
|Study Completion Date:||January 2005|
|Primary Completion Date:||January 2005 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00985010
|General Hospital "Dr. Darío Fernández Fierro"|
|Mexico, D.f., Mexico, 03900|
|Principal Investigator:||Hugo Mendieta Zerón, PhD||Materno-Perinatal Hospital of the State of Mexico|
|Study Director:||Camilo Rios Castañeda, PhD||National Institute of Neurology and Neurosurgery|
|Study Chair:||Mónica Rodríguez Rodríguez, MD||General Hospital "Dr. Darío Fernández Fierro"|